Bottom line
IBBQ vs BIB: the short answer
IBBQ (Invesco Nasdaq Biotechnology ETF) and BIB (ProShares Ultra Nasdaq Biotechnology) share a meaningful slice of their top holdings — about 51% by weight.
IBBQ is cheaper at 0.19% vs 0.95% — a difference of $76 a year per $10,000 invested.
Over one year, BIB returned +59.3% vs −0.6% for IBBQ (reporting dates differ).
Updated Nov 19, 2026
IBBQ vs BIB side by side
| IBBQ | BIB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | ProShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.19% | 0.95% |
| Annual cost per $10k | $19 | $95 |
| 10-yr cost on $10k (prospectus) | $242 | $1,401 |
| Max front load | None | None |
| 12b-1 fee | — | — |
| 1-yr return | −0.6% | +59.3% |
| 5-yr return (annualized) | — | −1.0% |
| 10-yr return (annualized) | — | +1.4% |
| Best quarter | +12.0% | +56.2% |
| Worst quarter | −11.7% | −42.7% |
| Net assets (fund) | $67.4M | $73.7M |
| Number of holdings | 261 | 267 |
| Portfolio turnover | 17% | 29% |
| Returns as of | Dec 31, 2024 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBBQ | BIB | Difference |
|---|---|---|---|
| 2024 | −0.6% | −10.0% | +9.4% |
| 2023 | +4.5% | −1.3% | +5.8% |
| 2022 | −10.2% | −28.6% | +18.4% |
Source: Fund prospectus bar charts
Holdings overlap
15 of IBBQ's top 25 holdings also appear in BIB's top 25.
| Holding | IBBQ | BIB |
|---|---|---|
| Gilead Sciences, Inc. | 7.39% | 4.66% |
| Vertex Pharmaceuticals Inc. | 7.38% | 4.65% |
| Amgen Inc. | 7.10% | 4.48% |
| Regeneron Pharmaceuticals, Inc. | 5.08% | 3.21% |
| Alnylam Pharmaceuticals, Inc. | 3.19% | 2.01% |
| Revolution Medicines, Inc. | 2.48% | 1.57% |
| Biogen Inc. | 2.29% | 1.44% |
| Illumina, Inc. | 1.98% | 1.25% |
| United Therapeutics Corp. | 1.94% | 1.22% |
| argenx SE | 1.89% | 1.19% |
| Insmed Inc. | 1.83% | 1.16% |
| Incyte Corp. | 1.53% | 0.97% |
| Viatris Inc. | 1.49% | 0.94% |
| Moderna, Inc. | 1.48% | 0.94% |
| Guardant Health, Inc. | 1.35% | 0.85% |
Source: SEC Form N-PORT
IBBQ top 10
- Invesco Private Prime Fund — 14.20%
- Gilead Sciences, Inc. — 7.39%
- Vertex Pharmaceuticals Inc. — 7.38%
- Amgen Inc. — 7.10%
- Invesco Private Government Fund — 5.48%
- Regeneron Pharmaceuticals, Inc. — 5.08%
- Alnylam Pharmaceuticals, Inc. — 3.19%
- Revolution Medicines, Inc. — 2.48%
- Biogen Inc. — 2.29%
- Illumina, Inc. — 1.98%
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
FAQ
What is the difference between IBBQ and BIB?
Which is cheaper, IBBQ or BIB?
Should I own both IBBQ and BIB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.